Beckman Coulter Life Sciences Acquires Assets of ReaMetrix India Pvt. Ltd

Beckman Coulter Life Sciences, an innovator in life science research, has acquired the flow cytometry business assets of ReaMetrix India Pvt. Ltd, a Bangalore-based life science technology company. The transaction provides Beckman Coulter Life Sciences with temperature-stable, single-dose, multi-color antibody cocktails targeting the HIV monitoring and clinical research markets.

ReaMetrix products complement the company’s flow cytometry portfolio with reagents that will simplify the sample preparation process and provide highly standardized reagent combinations to cytometry laboratories around the globe.

“This acquisition provides both immediate opportunity and long-term value,” said Mario Koksch, vice president and general manager of the Cytometry Business Unit for Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within two key segments for flow cytometry—HIV monitoring and clinical research.”

“Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation,” said Bala S. Manian, CEO of ReaMetrix India Pvt. Ltd. “The development of room temperature stable unitized flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world.”

ReaMetrix products are among the first dry temperature-stable flow cytometry reagents CE marked for in vitro diagnostic use in Europe. The diagnostic reagents are not currently available or cleared for use in the United States.